The Readout Loud
Ein Podcast von STAT - Donnerstags
350 Folgen
-
326: Crypto for CRISPR, a new RNAi startup, & a Nobel for AI
Vom: 10.10.2024 -
325: Biden's health care AI czar, a new obesity company, and its dealmaking CEO
Vom: 3.10.2024 -
From Tradeoffs: Race to the Bottom
Vom: 28.9.2024 -
324: Genentech's cancer pivot, Pfizer's sickle cell withdrawal, and a new schizophrenia drug
Vom: 26.9.2024 -
323: Cannabinoids for weight loss, a cancelled ad comm, and the Fed lowers interest rates
Vom: 19.9.2024 -
322: A new threat to Merck's blockbuster cancer treatment, Moderna's cutbacks, and obesity drugs for kids
Vom: 12.9.2024 -
321: Summit's upcoming cancer results, Recursion's mixed data, and the next big obesity target
Vom: 5.9.2024 -
320: Jim Wilson's next venture, a surprise startup shutdown, & Lilly's Zepbound strategy
Vom: 29.8.2024 -
From "Say More": What Happens When AI Decides Your Medical Coverage
Vom: 23.8.2024 -
319: BioMarin's executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion's AI bona fides
Vom: 22.8.2024 -
318: Drug pricing drops & psychedelics under fire
Vom: 15.8.2024 -
317: VC struggles, drug pricing negotiations, & Novo's abrupt Wegovy decision
Vom: 8.8.2024 -
316: The long journey to make malaria vaccines, and Sarepta's ties with patient advocates
Vom: 1.8.2024 -
315: UnitedHealth's doctor empire, an FDA departure, and Viking's obesity moves
Vom: 25.7.2024 -
314: JD Vance's biotech ties, Cassava resignations, and insulin shortages
Vom: 18.7.2024 -
313: Biotech layoffs, founder-focused VC, & a big pharma exit
Vom: 11.7.2024 -
312: Medicare coverage for GLP-1 drugs, AI, and health care at the presidential debate
Vom: 27.6.2024 -
311: Fauci's memoir, Alnylam's tenuous trial, and a mid-year review
Vom: 20.6.2024 -
310: Duchenne gene therapy setback, Alzheimer's drug endorsement & why a STAT reporter buys weed (for journalism)
Vom: 13.6.2024 -
309: Psychedelics at the FDA, ASCO recap, & MorphoSys update
Vom: 6.6.2024
STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.
